









Markets
/
Stocks
/
nasdaq-aytu
/

Aytu Biopharma Inc

AYTU



View Detailed Chart

2.550USD

+0.080+3.24%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

25.28MMarket Cap

LossP/E TTM



Aytu Biopharma Inc

2.550

+0.080+3.24%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+3.24%

5 Days

+10.87%

1 Month

+31.44%

6 Months

+27.50%

Year to Date

+50.00%

1 Year

+84.78%

View Detailed Chart

TradingKey Stock Score of Aytu Biopharma Inc

Currency: USD Updated: 2025-12-19

Key Insights

Aytu Biopharma Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.17.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aytu Biopharma Inc's Score

Industry at a Glance

Industry Ranking

77 / 158

Overall Ranking

192 / 4582

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.167

Target Price

+309.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aytu Biopharma Inc Highlights

StrengthsRisks

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Growing

The company is in a growing phase, with the latest annual income totaling USD 66.38M.

Undervalued

The company’s latest PE is -1.16, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 95.12K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.49.